Business Context and Reporting Period
Company: Coherus Oncology, Inc. (formerly Coherus BioSciences, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Coherus is a commercial-stage innovative oncology company focused on immuno-oncology. In May 2025, the company changed its name to reflect its exclusive focus on proprietary innovative medicines following the divestiture of its biosimilar businesses (UDENYCA, YUSIMRY, and CIMERLI). The company's primary commercial product is LOQTORZI (toripalimab-tpzi), an anti-PD-1 inhibitor approved for nasopharyngeal carcinoma (NPC). The pipeline includes two mid-stage candidates: casdozokitug (IL-27 antagonist) and tagmokitug (CCR8 antagonist).
Key Financial Metrics
| Metric | 2025 (in thousands) | 2024 (in thousands) |
|---|---|---|
| Total Net Revenue (Continuing Ops) | $42,172 | $26,389 |
| LOQTORZI Revenue | $40,836 | $19,131 |
| Gross Margin | 67% | 67% |
| Net Loss from Continuing Operations | $(183,124) | $(215,394) |
| Net Income from Discontinued Operations | $351,148 | $243,901 |
| Total Net Income | $168,024 | $28,507 |
| Cash, Cash Equivalents, and Marketable Securities | $172,125 | $125,987 |
| Accumulated Deficit | $(1,382,969) | $(1,550,993) |
| Total Financial Liabilities | $51,200 | $293,670 |
Note: The 2025 financial results include a significant gain from the sale of the UDENYCA business, classified as discontinued operations. Continuing operations reflect the oncology-focused business.
Material Changes vs. Prior Period
- Strategic Divestiture: Completed the sale of the UDENYCA business to Intas Pharmaceuticals on April 11, 2025, for $483.4 million in cash. This transaction triggered a strategic shift, resulting in the reclassification of biosimilar operations as discontinued operations.
- Revenue Growth: LOQTORZI revenue increased by 113% year-over-year (from $19.1M to $40.8M) driven by volume growth following its January 2024 launch.
- Debt Reduction: Utilized proceeds from the UDENYCA sale to repay substantially all outstanding 2026 Convertible Notes and buy out royalty rights on UDENYCA net sales, significantly reducing total financial liabilities from $293.7M in 2024 to $51.2M in 2025.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses decreased by $24.9M (20%) due to lower headcount and the absence of impairment charges related to terminated out-license programs that impacted 2024. Research and Development (R&D) expenses increased by $17.1M (19%) primarily due to accelerated development of tagmokitug and casdozokitug.
- Capital Raise: In February 2026 (subsequent to period end), the company completed a public offering raising approximately $47.0 million in net proceeds.
Guidance, Outlook, and Risks
Outlook: Management expects net revenue from continuing operations in 2026 to be higher than in 2025 due to continued LOQTORZI growth. Fixed R&D expenses are expected to be lower in 2026 due to rebalancing manufacturing activities and reduced headcount. The company believes its current cash position and product sales will fund operations for at least the next 12 months.
Key Risks and Contingencies:
- Profitability: The company has a limited history of profitability and an accumulated deficit of $1.4 billion. Future profitability depends on LOQTORZI sales growth and the successful development of pipeline candidates.
- UDENYCA Earnouts: The company is eligible for two potential earnout payments of $37.5 million each from Intas, contingent on UDENYCA net sales thresholds. Receipt of these payments is not guaranteed.
- Regulatory and Clinical: Pipeline candidates (casdozokitug, tagmokitug) face significant risks regarding clinical trial success and regulatory approval. LOQTORZI faces competition from other PD-1/PD-L1 inhibitors, including penpulimab-kcqx approved in April 2025.
- Manufacturing: The company is transitioning biomanufacturing from offshore to onshore (U.S.) models, which carries risks of cost increases and supply disruptions.
- Healthcare Reform: The Inflation Reduction Act (IRA) and the One Big Beautiful Bill Act (OBBBA) may impact pricing, reimbursement, and Medicaid funding, potentially affecting sales.
Investor Verification Checklist
- LOQTORZI Adoption Rate: Verify the trajectory of LOQTORZI sales growth and market share in the nasopharyngeal carcinoma (NPC) indication against the estimated $250 million market opportunity.
- UDENYCA Earnout Probability: Assess the likelihood of achieving the $300 million and $350 million net sales thresholds required to trigger the $75 million in potential earnout payments from Intas.
- Pipeline Milestones: Monitor upcoming data readouts for casdozokitug (Phase 2 in HCC) and tagmokitug (Phase 1b/2a in solid tumors) to validate the increased R&D spend.
- Manufacturing Transition: Confirm the timeline and cost implications of the onshoring initiative for LOQTORZI and pipeline candidates.
- Liquidity Runway: Re-evaluate the cash runway post the February 2026 equity offering ($47M proceeds) against the burn rate of continuing operations.